36 results about "Intrahepatic Cholangiocarcinoma" patented technology

The invention relates to a human intrahepatic cholangiocarcinoma cell line with high tumorigenic ability and application thereof. The invention discloses a novel human intrahepatic cholangiocarcinoma cell line which grows stably and has clear quantity of generations and high tumorigenic rate; the human intrahepatic cholangiocarcinoma cell line can form an adenoid tumor in vivo and can be used for in-vivo and in-vitro research on human intrahepatic cholangiocarcinoma; a foundation is laid for constructing an in-vivo animal model, disclosing a tumor malignant progression mechanism, screening related biomarkers and developing novel intrahepatic cholangiocarcinoma resisting medicines.

The invention relates to a human intrahepatic duct cancer cell line and an application thereof. The human intrahepatic duct cancer cell line LICCF is established according to the invention, is clear and definite in algebra, does not have cross contamination, shows unique sensitivity to an inhibitor of a PI3K / mTOR passage and an inhibitor of an MEK1 / 2 passage, has high drug resistance to 5-FU, cis-platinum and FGFR inhibitors, and can be used for establishing in vivo and in vitro tumor drug experiment and drug resistance models, so that an experimental basis is provided for revealing a human intrahepatic duct cancer drug resistance mechanism, reversing the appearance of drug resistance, developing new anticancer drugs and screening human intrahepatic duct cancer related biological markers.

The present application provides a prediction system for prognosis and survival of patients with intrahepatic cholangiocarcinoma, including: an acquisition module and a prediction module, and the acquisition module and the prediction module are connected in a wireless and / or wired manner. The prediction system can use the promoter methylation score as the only variable to predict the survival of patients with intrahepatic cholangiocarcinoma, and can also predict the survival of intrahepatic cholangiocarcinoma based on multiple variables including the promoter methylation score. The prognostic survival period of cancer patients has the advantages of high accuracy, strong reliability, and stable prediction.

The present invention provides a method for constructing a model for predicting the survival rate of patients with intrahepatic cholangiocarcinoma, comprising the following steps: 1) providing DNA methylation sequencing data of intrahepatic cholangiocarcinoma; 2) sequencing the DNA methylation Analyze the data and screen out several related promoter regions of intrahepatic cholangiocarcinoma; 3) use the several related promoter regions of intrahepatic cholangiocarcinoma to establish a model for predicting the survival rate of patients with intrahepatic cholangiocarcinoma . Through the prognostic markers of DNA methylation in patients with intrahepatic cholangiocarcinoma, the markers of DNA methylation are used as independent variables, and patients are divided into high mortality and low mortality risk groups. After experimental verification, this paper The invented model construction method can be used to predict the overall survival rate of patients with intrahepatic cholangiocarcinoma after surgery, and provide individualized adjuvant treatment strategies for patients with intrahepatic cholangiocarcinoma.

The invention discloses a FISH probe set for detecting FGFR2 fusion and its application, including a 5' end probe set and a 3' end probe set; The BAC clone of the sequence is used as a template and amplified with random primers, in which each probe is modified with the first reporter group; the 3' end probe group is based on the BAC of the nucleotide sequence on the centromere side of the FGFR2 gene Clones are used as templates and amplified with random primers in which each probe is modified with a second reporter group. The invention is quick and easy to operate, accurate and reliable in detection results, can accurately detect all fusion types of the FGFR2 gene, provides a reference for the treatment plan of patients with intrahepatic cholangiocarcinoma, is beneficial to individualized targeted therapy for patients, reduces drug side effects, and improves patient survival Quality, reduce family and social burden, suitable for large-scale promotion and application.

The invention discloses a product and a method for identifying hepatocellular carcinoma and intrahepatic cholangiocarcinoma based on an MANF as a marker. The invention provides an application of a system for detecting the expression quantity of the MANF in preparation of products for identification or supplementary identification of hepatocellular carcinoma patients and intrahepatic cholangiocarcinoma patients. The hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are identified by taking the MANF as the marker and detecting the expression level of the MANF in a primary hepatocellular carcinoma tissue, a method and an index for effectively identifying the hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are built, the sensitivity is 92.5% and the specificity is 74.7%. A foundation is laid for targeted appropriate treatment and improvement of prognosis of the patients to improve the living quality of the patients and to reduce the economic burden of the patients.

The invention relates to the technical field of medical bioengineering, and aims to provide an application of MMP7, CTSE or LAMC2 proteins in preparation of an intrahepatic cholangiocarcinoma diagnosis reagent. The application is used for preparing a reagent capable of identifying and diagnosing intrahepatic cholangiocarcinoma and distinguishing primary hepatocellular carcinoma by using at least one of the MMP7, the CTSE or the LAMC2 proteins, which means the identification and the distinguishing of the hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are achieved by using thethree proteins independently or in a combined manner. According to the application of the MMP7, the CTSE or the LAMC2 proteins in preparation of the intrahepatic cholangiocarcinoma diagnosis reagent,the reagent or a kit product is prepared from the three proteins, the expression level of the proteins in blood is detected by an immunological related method and is used as a basis for diagnosing anintrahepatic cholangiocarcinoma marker. The application of the MMP7, the CTSE or the LAMC2 proteins in preparation of the intrahepatic cholangiocarcinoma diagnosis reagent can accurately and specifically judge the possibility of the intrahepatic cholangiocarcinoma, benign biliary diseases, the hepatocellular carcinoma and health status of a subject, and provides a basis of the next diagnosis and treatment scheme for doctors.

The invention discloses an application of using CtBP2 as a marker in the preparation of diagnostic products for hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and belongs to the technical field of biomedicine. The research results of the present invention show that most high-moderately differentiated HCCs are negative for CtBP2, and only a few poorly differentiated HCCs are positive; while in ICC, CtBP2 is diffusely strongly positive. Therefore, CtBP2 can be used as a marker to prepare related products for the identification and diagnosis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma, thereby providing a new method for the identification, diagnosis or drug efficacy evaluation of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. objective indicators.